Feed ARKAF
AR

Arkema S.A. ARKAF OTC · Basic materials · France

$66.72 +0.00% +$0.00

Summary

44 / 100 · Bulios Score

What speaks for it

  • The share price is below the Bulios Fair Price.
  • It has been profitable 6 years in a row.

What to watch

  • Earnings per share fell by 60% a year over the last 3 years.
  • It pays out more in dividends than it earns: 357% of profit.
  • It missed profit estimates 6 times in the last 8 quarters.
  • Out of every 100 EUR of revenue, only 0.9 EUR is left as net profit.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks cheap
Bulios Fair Price
Undervalued Price today $66.72

By our assumptions the business is worth more than its shares cost today.

P/E today 56.9
Chemicals - Specialty industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 56.9 EUR for 1 EUR of yearly profit.

Valuation in detail

Is it growing?

It is shrinking

Revenue (EUR)

Diluted EPS (EUR)

  • Analyst estimate

Revenue grew by 2.8% a year over 5 years. Over the last 3 years it fell by 7.8% a year. For the next fiscal year analysts expect revenue to fall by 0.4%. Earnings per share fell by 60% a year over the last 3 years.

Growth in detail

Does it make money?

Reasonably

Where 100 EUR of revenue goes

Net profit, industry median (Chemicals - Specialty) 6.0 EUR

Out of every 100 EUR of revenue, 0.9 EUR is left as net profit.

Profitability in detail

Is it financially healthy?

Debt is a burden

Repaying all its debt would take 18.4 years of free cash flow. Its debt is larger than its cash.

Financial health in detail

Does it pay a dividend?

High, at risk
Yield
6.28%
Paid out of profit
357%
Raised in a row
4 years

You receive $4.19 per share a year. The payout is more than the company can comfortably cover.

Dividends in detail

What do analysts expect?

Mildly positive

No analyst has published a price target.

50% of the analysts recommend buying.

Analysts in detail

What does it earn on?

By product

The company reports no revenue by product.

By region

The company reports no revenue by region.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy